At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
Salbutamol HFA-152a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Dose Two-way Cross-over Study in Healthy Participants to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152a and HFA-134a
In Brief
A Phase 1 clinical trial evaluating Salbutamol HFA-152a and Salbutamol HFA-134a for Asthma. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This study will be conducted to compare the PK of salbutamol administered via metered dose inhalers (MDI) containing propellants 1,1-difluroethane (HFA-152a) and 1,1,1,2-tetrafluoroethane (HFA-134a) in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedMar 2023
Enrollment StartApr 2023
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 30, 2023
Enrollment StartApr 3, 2023
Primary CompletionMay 21, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.3 years ago
Interventions
Salbutamol HFA-152adrug
Salbutamol HFA-152a will be administered.
Salbutamol HFA-134adrug
Salbutamol HFA-134a will be administered.